Granulocyte-colony stimulating factor (G-CSF) promotes mobilization of CD11b
+

Gr1
+ myeloid cells and has been implicated in resistance to anti-VEGF therapy in mouse models. High G-CSF production has been associated with a poor prognosis in cancer patients. Here we show that activation of the RAS/MEK/ERK pathway regulates G-CSF expression through the Ets transcription factor. Several growth factors induced G-CSF expression by a MEKdependent mechanism. Inhibition of G-CSF release with a MEK inhibitor markedly reduced G-CSF production in vitro and synergized with anti-VEGF antibodies to reduce CD11b
+
Ly6G
+ neutrophil mobilization and tumor growth and led to increased survival in animal models of cancer, including a genetically engineered mouse model of pancreatic adenocarcinoma. Analysis of biopsies from pancreatic cancer patients revealed increased phospho-MEK, G-CSF, and Ets expression and enhanced neutrophil recruitment compared with normal pancreata. These results provide insights into G-CSF regulation and on the mechanism of action of MEK inhibitors and point to unique anticancer strategies.
angiogenesis | microenvironment | tyrosine kinase A ngiogenesis is recognized as an important aspect of tumorigenesis. VEGF-A (hereafter called VEGF) is a wellcharacterized regulator of normal and pathological angiogenesis (1) . Strategies targeting VEGF signaling have been shown to inhibit tumor angiogenesis in a variety of animal models (2) . Several VEGF pathway inhibitors have demonstrated clinical efficacy and have been US Food and Drug Administrationapproved for treatment of several malignancies. However, like most cancer therapies tested to date, patients treated with such inhibitors eventually progress (3) .
The stroma can facilitate tumor growth and angiogenesis through a variety of mechanisms, including production of cytokines and inflammatory cell recruitment (4, 5) . Also, much evidence supports the notion that various bone marrow-derived cell types play important roles in regulating tumor angiogenesis (4) . A population of myeloid cells, identified in the mouse by the expression of the cell surface markers CD11b and Gr1, has generated considerable interest because of its ability to facilitate tumor angiogenesis and metastasis (6, 7) . Furthermore, subsets of CD11b + Gr1 + cells, termed myeloid-derived suppressor cells, have the ability to suppress T-cell responses and thus they may also promote tumor progression through escape from immune surveillance (8) .
Previous studies have shown that tumor recruitment of CD11b + Gr1 + cells mediates refractoriness to anti-VEGF therapy in several murine models (9) . The hematopoietic growth factor granulocyte-colony stimulating factor (G-CSF) (reviewed in ref. 10 ) was reported to be a major mediator of expansion and mobilization of CD11b + Gr1 + cells (11, 12) . G-CSF-mobilized CD11b + Gr1 + cells also produce a variety of factors that facilitate primary tumor growth and metastasis, including MMP9, S100A8, and S100A9 (13) as well as proangiogenic factors such as Bv8 (12) .
In this study, we sought to elucidate the signaling pathways that control G-CSF expression in tumor cells. We show that the RAS/ RAF/MEK pathway is constitutively active in many cancer cells that produce high G-CSF levels and that expression of the Ets2 transcription factor is directly correlated with high G-CSF production. Treatment with a MEK inhibitor substantially reduced G-CSF release and myeloid cell mobilization. We also provide evidence that combination treatments of MEK inhibitor and anti-VEGF significantly decreased growth and tumor angiogenesis in anti-VEGF-resistant tumor models, including a genetically engineered mouse model (GEMM) of Kras-driven pancreatic ductal adenocarcinoma (PDAC).
Results
Ets2 Transcriptional Regulation of G-CSF in Cancer. To identify transcription factors regulating G-CSF release in cancer cells, we expressed a G-CSF promoter-driven luciferase reporter in the 4T1-related mouse breast cancer cell lines (14) . Consistent with our previous findings (13) that the nonmetastatic 67NR and 168FARN cells have undetectable G-CSF levels, whereas the metastatic 4T07 and 4T1 cells express high G-CSF levels, we detected strong luciferase activation in 4T07 and 4T1 but not in 67NR or 168FARN cells (Fig. S1 A and B) . We next identified conserved transcriptional binding sites at the G-CSF promoter region upstream of the ATG initiation codon (Fig. S1D) . We then performed site-directed mutagenesis to screen for potential transcriptional binding sites that might regulate G-CSF transcription. We identified the binding sites of two Ets transcriptional consensuses-ACCCg (−232) and TAAAc (−101)-binding sites and verified that these two sites are important mediators of G-CSF expression. Site-directed mutagenesis of either ACCCg or TAAAc significantly decreased luciferase activity (Fig. 1A) . Importantly, mutating both sites (bar 4) did not further reduce luciferase activity, suggesting that the two Ets binding sites control synergistically G-CSF transcription (Fig. 1A) . Ets transcription factors have been reported to be highly expressed in human cancers (15) . We found that Ets2 protein levels are elevated in 4T07 and 4T1 compared with 67NR and 168FARN l cells (Fig. S1C) . Enforced expression of Ets2 in 4T1 cells further increased G-CSF expression (Fig. 1B) . Targeting Ets2 with shRNAs directly correlated with reduction in G-CSF expression (Fig. 1C) . To confirm Ets2-induced G-CSF expression, we coexpressed either WT Ets2 or a dominant negative Ets2 with the G-CSF promoter-driven luciferase reporter construct in 4T1 cells. The dominant negative Ets2 abolished G-CSF promoter activity (Fig. 1D ) and decreased G-CSF levels (Fig. 1E) , whereas WT Ets2 further increased G-CSF expression. To investigate whether Ets2 directly binds to the G-CSF promoter, we performed ChIP analysis in 67NR and 4T1 cells. We evidenced direct binding of Ets2 to the G-CSF promoter in 4T1 but not in 67NR cells by quantitative PCR (Fig. 1F) . Next, we performed immunohistochemistry to investigate whether Ets2 and G-CSF are overexpressed in human cancers, including ovarian, bladder, head and neck, and pancreatic adenocarcinomas. We validated antibodies recognizing G-CSF and Ets2 by immunohistochemistry and quantitative PCR (Fig. S1 D and E) . As shown in Fig. 1G , Ets2 and G-CSF are coexpressed in biopsies of multiple human cancers.
Activation of the RAS Signaling Pathway Drives G-CSF Expression.
The Ets proteins are important for many cellular processes, including cell proliferation, apoptosis, hematopoiesis, angiogenesis, and tumorigenesis (16) . In normal and cancer cells, the RAS/RAF/MEK signaling pathway increases Ets2 activity through ERK-dependent phosphorylation (16) . Because the RAS pathway activates Ets2 transcriptional activity, we investigated whether this pathway is activated in 4T1-related cell lines. Our analysis indicates that the RAS pathway is active in 4T1 but not in 67NR cells, as assessed by BRAF and ERK phosphorylation (Fig. S2A) . We then tested whether inhibiting MEK activity can suppress G-CSF release in 4T1 cells. To this end, we used the MEK inhibitor (MEKi) GDC-0973/XL518. This agent is a potent, selective, orally active inhibitor of MEK1/2 with an IC 50 of <1 nM in vitro (17) and is currently undergoing clinical trials (18) . G-CSF production by 4T1 cells was directly correlated with ERK phosphorylation levels, which could be modulated by treatment with different concentrations of MEKi (Fig. S2B) . The RAS signaling pathway controls growth, proliferation, and survival of cancer cells by activating multiple downstream effectors including the RAF/MEK/ERK and the PI3K pathways (19) . Our data indicate that the RAF/MEK/ERK, but not the PI3K pathway, is responsible for G-CSF overexpression in cancer cells (Fig. S3 A and B) .
G-CSF Expression in Mouse and Human Cancer Cell Lines. Mutations in the RAS signaling pathway have been detected in ∼30% of all human cancers (19, 20) . We examined G-CSF expression profiles in mouse Kras mutant cancer cell lines. Many of the cell lines tested expressed high G-CSF levels in a MEK-dependent activation manner (Figs. S2C and S3A). In contrast, PI3Ki treatment had no effect on G-CSF expression, confirming that even though PI3K pathway is downstream of RAS, it does not play a role in G-CSF expression. Interestingly, in agreement with previous studies showing that inhibiting RAF could further activate the MAPK pathway (21, 22) , we found that a RAF inhibitor, GDC-0879, further increased ERK phosphorylation and induced G-CSF expression in mouse cancer cell lines (Figs. S2C and S3A). It remains to be established whether G-CSF increases in metastatic melanoma patients treated with RAF kinase inhibitors play a role in resistance to this therapy. We next screened 31 human cancer cell lines representing six different cancer types. We found that 45% (14/31) of the human cell lines express high G-CSF (Table S1 ). Eight of 13 G-CSF-positive cell lines have mutations in KRAS (Calu-1, Calu-3, Calu-6, EBC-1, HCC-15, SW1463, H2122, MDA-MB231) (23, 24) . Three cell lines have receptor tyrosine kinase amplifications or mutations that lead to activation of the RAS pathway, as measured by ERK phosphorylation. These include EGFR mutations in the H1975 lung cancer cell line (25) , epidermal growth factor receptor (EGFR) and FGF amplification in the 5637 bladder cancer cell line (26) and eriythropoietin receptor (EpoR) amplification the H838 lung carcinoma cell line. The bladder cell line BFTC-095 has an active NRAS mutation (27) and UM-UC-1 has a constitutively active RAS pathway (Fig. S3B ). Similar to the mouse cancer cell lines, MEK inhibition reduced G-CSF release in a dose-dependent fashion in all of the G-CSF-positive cell lines tested (Fig. S3B) . RAF inhibitor GDC-0879 treatment resulted in activation of the MAPK pathway and G-CSF expression in a subset of human cancers. Similar to the mouse cancer cell lines, PI3K inhibitor treatment had no effect on G-CSF expression (Fig. S3B ).
Multiple Growth Factors Induce G-CSF Expression. We sought to identify factors responsible for inducing G-CSF expression. We previously reported that, whereas Lewis lung carcinoma (LLC) cells secrete very low amounts in vitro, LLC tumors produce high G-CSF levels in vivo (12) . We hypothesized that growth factors produced within the tumor microenvironment might induce G-CSF expression in LLC cells. To identify candidate regulatory factors, we incubated LLC cells in vitro with a panel of growth factors. Several members of the platelet-derived growth factor ( activation (18) . Accordingly, MAPK, as measured by ERK phosphorylation, was activated in LLC cells upon stimulation with the different FGFs. MEKi treatment strongly inhibited ERK phosphorylation and G-CSF release in the presence of FGFs (Fig. 2B) . Mutations or amplifications of the FGF receptors have been reported in many human cancer types (29) ; therefore, we investigated whether enforced FGF receptors expression is sufficient to induce G-CSF. Expression of all four FGF-receptors, FGFR1-4, could induce G-CSF expression (Fig. 2C ). FGFR4 and Ets2 coexpression could induce G-CSF release in mouse pancreatic cancer cells in vitro. MEKi, but not PI3K inhibitor, inhibits FGFR4-enforced G-CSF expression (Fig. 2D) . Human PDACs have a large stromal component, including alpha-smooth muscle actin (aSMA)-positive myofibroblast-like stellate cells (5) . Accordingly, mouse PDAC tumors are highly positive for aSMA markers (Fig. 2E) . Because the stroma has been proposed to be responsible for PDAC pathogenesis and resistance to chemotherapeutic treatments, we hypothesized that FGFs could stimulate aSMA + cells to release G-CSF. We purified aSMA/CD105 double-positive myofibroblast-like cell fractions (30) that are negative for CD31 to exclude endothelial cell contamination from tumors. We confirmed that these cells express aSMA (Fig. 2F) and CD105 (Fig. 2G ) and are negative for CD31 (Fig. 2 F and G ;Pdx-Cre ductal adenocarcinoma genetically engineered mouse model (31, 32) , previously shown to be resistant to anti-VEGF monotherapy (32) . PDAC tumor-bearing mice had higher G-CSF plasma levels than naive WT animals (Fig. S5B) . Administration of MEKi significantly reduced G-CSF levels in the plasma of tumor-bearing mice at both 7 h and 7 d after treatment (Fig. S5A) . We next profiled cytokines and growth factors released in the plasma of PDAC mice and compared them with MEKi-treated or naive WT animals. In addition to G-CSF, many inflammatory growth factor and cytokine levels, including basic FGF, TNF-α, GM-CSF, KC (CXCL1), and IL-17, were increased (Fig. S5B ). Among these factors, only TNF-α and G-CSF decreased significantly on day 7 after MEKi treatment ( Fig. S5B and Table S2 ). Importantly, MEKi administration resulted in decreased CD11b + Ly6G + neutrophil mobilization in the peripheral blood of Kras-driven PDAC GEMM (Fig. S5C ). 
G-CSF Induces CD11b
Gr1
+ myeloid population drive resistance to anti-VEGF therapy. We used antibodies that specifically recognize Ly6G + neutrophils (33, 34) , and Ly6C + monocytes (13) . In addition, we used G-CSF-R −/−
RAG2
−/− mice, which exhibit reduced Ly6G + neutrophil populations (35) . We confirmed that naive G-CSF-R −/−
−/− mice have a significant reduction in CD11b
+
Ly6G
+ neutrophils compared with G-CSF-R +/+
RAG2
−/− mice (Fig. S6A ), but show no significant differences in the percentages of CD11b 
−/− mice (Fig. 3A) . Also, CD11b + Ly6G + neutrophil reduction alone was not sufficient to reduce tumor growth. In contrast, anti-VEGF antibody treatment significantly reduced tumor growth in the G-CSF-R −/−
−/− mice (Fig. 3A) . Therefore, these data suggest that the ability of anti-VEGF to reduce tumor growth is directly correlated with decreased CD11b
+
Ly6G
+ neutrophil mobilization (Fig. 3B) .
MEKi Treatment Is Additive with Anti-VEGF in Inhibiting LLC Tumor
Growth. In agreement with our previous finding (12), LLC tumors were refractory to anti-VEGF therapy (Fig. S7A) . MEKi or anti-G-CSF antibody single-agent treatment significantly inhibited G-CSF levels (Fig. S7B ) and directly correlated with reduction in Cd11b + Ly6G + neutrophil mobilization in the peripheral blood of LLC tumor-bearing animals (Fig. S7C) . Combination treatment of MEKi plus anti-VEGF significantly reduced tumor growth compared with anti-Ragweed or anti-VEGF monotherapy (Fig.  S7A) . Importantly, combination treatment of MEKi plus anti-VEGF or anti-G-CSF plus anti-VEGF resulted in marked reduction in angiogenesis (Fig. S7 D and E) as measured by CD31 + endothelial cell density relative to anti-Ragweed-treated animals. 
Combined Inhibition of G-CSF or MEK with Anti-VEGF Therapy Is
Efficacious in a PDAC Allograft Model. We next tested combination therapies using MEKi and anti-VEGF or anti-G-CSF and anti-VEGF in PDAC mouse models. Anti-G-CSF or MEKi alone significantly reduced CD11b + Ly6G + neutrophil mobilization, but had little effect on tumor growth (Fig. 3 C and E) . Similarly, even though MEKi plus anti-G-CSF combination therapy significantly reduced CD11b
+
Ly6G
+ neutrophil mobilization, we did not observe significant reduction in tumor growth compared with monotherapies (Fig. 3C) . However, we observed significant reductions in tumor growth following combination of MEKi plus anti-VEGF or anti-G-CSF plus anti-VEGF (Fig. 3C) . Targeting G-CSF combined with anti-VEGF therapy significantly reduced angiogenesis as measured by CD31 + endothelial cells in tumors (Fig. 3F) . Indeed, quantitative analysis revealed marked reduction in microvessel density in the combinations (Fig. 3G ) compared with anti-Ragweed-treated group.
Combining MEKi or Anti-G-CSF with Anti-VEGF Antibody Increases
Survival in a Kras-Driven PDAC GEMM. We investigated whether combination treatments with either MEKi and anti-VEGF or anti-G-CSF and anti-VEGF could prolong overall survival in the K-ras LSL-G12D ; p16/p19 fl/fl ;Pdx-Cre PDAC GEMM (31) . We first examined the myeloid cell subpopulations in the PDAC GEMM at day 7 after drug treatments (Fig. 4 C and D) . Inhibition of G-CSF with either MEKi or anti-G-CSF significantly reduced CD11b + Ly6G + neutrophils (Fig. 4C) in the peripheral blood. However, neutralizing G-CSF did not have a significant effect on the CD11b
+
Ly6C
+ monocyte population (Fig. 4D , bars 4 and 6), suggesting that the CD11b
+
Ly6C
+ monocyte are not included in the G-CSF-induced myeloid cell mobilization in the PDAC GEMM. To investigate survival in PDAC mice, we first stratified the cohorts by performing G-CSF ELISA and microultrasound analysis as previously described (32, 36, 37) . Consistent with our allograft studies, PDAC GEMM cohorts that received MEKi or anti-G-CSF as single agent therapy had no significant survival benefit relative to control (Fig. 4A) , despite a marked reduction in the CD11b
+
Ly6G
+ neutrophil population (Fig. 4C) . Consistent with previous reports (32, 38) , PDAC GEMM was resistant to anti-VEGF monotherapy (Fig. 4A) . In contrast, combination therapies significantly improved median survival compared with control vehicle. MEKi and anti-VEGF combination treatment resulted in increased survival (median survival 3.6 wk vs. 2.3 wk for controls; P = 0.002). Similarly, anti-G-CSF and anti-VEGF combination resulted in a median survival of 3.7 wk, compared with 2.3 wk in the control group (P = 0.015) (Fig. 4A) . We also performed high-resolution microultrasound imaging to measure tumor volumes in the cohorts and calculated the daily fold change in the treated animals (Fig. S8) . Anti-G-CSF plus anti-VEGF or MEKi plus anti-VEGF combination therapy resulted in slower tumor growth compared with control single-treatment arms (Fig. 4B) .
MEK Pathway Activation and Neutrophil Recruitment in Human PDAC.
The majority of patients diagnosed with PDAC harbor KRAS mutations (20) . We investigated whether there are any correlations between high G-CSF expression, phospho-MEK (pMEK), and phospho-FGFR (pFGFR) in human PDAC biopsies. First, we validated antibody-binding specificity to MEK and FGFR phosphorylation by performing control immunohistochemical staining experiments (Fig. S9) . In 116 patient PDAC biopsies, 83% of the samples were positive for G-CSF (97/116), 81% were positive for pMEK (94/116), and 25% were positive for pFGFR (27/116) ( Fig.  S10 A-D) . Immunohistochemical staining revealed coexpressions of pMEK and G-CSF (82%) or pFGFR and G-CSF (26%) in the human PDAC biopsies (Fig. S10F) . Similar to our Kras-driven PDAC GEMM, we found significant increases in neutrophil recruitment in G-CSF-positive human PDAC biopsies (Fig. S10E) .
Discussion
In humans, elevated plasma G-CSF levels have been reported in a variety of solid tumors and may be associated with severe leukocytosis and a poor prognosis (39) . Anti-G-CSF treatment results in a dramatic reduction in CD11b + Gr1 + myeloid cells and Bv8 levels in tumor and plasma of tumor-bearing mice (12, 13) . Although some mechanisms of G-CSF regulation had been described in the literature (40) , the precise signal transduction pathways regulating G-CSF in cancer cells have not been elucidated. In this study, we identified MEK activation as the major mechanism leading to G-CSF expression in tumor and stromal cells. Our analysis in 4T1-related mouse breast cancer cells revealed that the Ets2 transcriptional factor directly binds to the G-CSF promoter and regulates its expression. Although targeting Ets2 transcriptional binding sites at the G-CSF promoter could abolish the majority of G-CSF expression, the inhibition was not complete. This could be attributed to activation of other signaling pathways that drive G-CSF expression, including NF-κB (41). Interestingly, Ets proteins are phosphorylated by MAPK through the activation of the FGFR pathway (16) . A recently study has shown that Ets2 transcriptional activity in tumorassociated fibroblasts is responsible for the recruitment of macrophages and for inducing tumor angiogenesis (42) . We show that enforced expression of Ets2 results in high G-CSF release in both tumor and stromal cells. Importantly, we document coexpression of Ets2 and G-CSF in multiple human tumor types. Therefore, targeting Ets2 activity in tumors might lead to G-CSF downregulation and favorable therapeutic outcomes for patients.
Because activation of the RAS/RAF/MEK signaling pathway resulted in enhanced G-CSF expression, we hypothesized that growth factors and cytokines produced by cells within the tumor microenvironment might activate G-CSF in tumor and stromal cells. Indeed, we show that several growth factors can induce G-CSF expression in a MEK-dependent manner. Levels of multiple inflammatory cytokines and growth factors were elevated in the peripheral blood of Kras-driven PDAC GEMM. Interestingly, these factors are strong inducers of the RAS/RAF/MEK pathway and therefore could stimulate G-CSF release in both tumor and stromal cells. Indeed, isolated PDAC tumor associated aSMApositive myofibroblast-like stellate cells could readily express G-CSF upon FGFs stimulation by a MEK-dependent mechanism. Further, in addition to cytokine-induced G-CSF release in the PDAC microenvironment, amplifications or mutations of FGFRs have been documented in many human cancers (43, 44) . Here we show that enforced expression of FGFRs in mouse PDAC cells can induce G-CSF release. Consistent with our in vitro findings, we observed constitutive activation of FGFR pathway, MEK phosphorylation and G-CSF overexpression in the majority of human PDAC biopsies. Taken together, these findings indicate that MEKi could target both tumor and stromal cells to reduce G-CSF expression. Because G-CSF activation is MEK-dependent, we hypothesized that targeting MEK activation could inhibit G-CSF expression in tumors and also increase tumor responses to anti-VEGF therapy. MEKi and anti-VEGF combination therapy significantly reduced tumor growth in multiple allograft models and prolonged survival in a Kras-driven PDAC GEMM. Currently, MEK inhibitors are undergoing clinical development for treatment of melanomas and other malignancies with tumor cell-intrinsic activation of the RAS pathway (17) . Our findings provide insights into the mechanism of action of these agents and indicate that they have the potential to have a major impact also on the tumor microenvironment (Fig. S11) .
We have previously reported that G-CSF is a major mediator of CD11b + Gr1 + myeloid cell expansion and mobilization and is an inducer of anti-VEGF resistance through activation of proangiogenic pathways (11, 12) . Neutralization of G-CSF resulted in dramatic reduction in CD11b
+
Gr1
+ cells in the plasma of tumorbearing mice (12, 13) . We further characterized the myeloid cells subpopulation that is responsible for G-CSF-induced resistance to anti-VEGF therapy. We used both G-CSFR −/− RAG2 −/− mice (35) and anti-G-CSF antibody or MEKi and found that CD11b 
Ly6G
+ neutrophil mobilization significantly contributes to anti-VEGF resistance therapy in multiple tumor models.
As already noted, a subset of CD11b
+
Gr1
+ myeloid cellsmyeloid-derived suppressor cells (8)-is able to suppress of T cell-dependent responses. Indeed, recent studies report that GM-CSF could induce CD11b
+
Gr1
+ cell mobilization and as a result suppress CD8 + T-cell functions in a Kras-driven PDAC GEMM (45, 46) . Interestingly, these studies reported that targeting GM-CSF expression alone in PDAC could reduce CD11b
+
Gr1
+ mobilization and block tumor development. In contrast, our study shows that targeting the CD11b 
Ly6C
+ monocytes is presented. Naive (n = 7), aRagweed (n = 7), aVEGF (n = 10), aG-CSF (n = 4), MEKi (n = 4), aVEGF+ aG-CSF (n = 3), and aVEGF+MEKi (n = 5); *P = 0.05. Error bars indicate SD.
agent failed to extend survival in tumor-bearing mice. In contrast, neutralizing G-CSF activity and G-CSF-induced CD11b + Ly6G + neutrophils was effective when combined with anti-VEGF in reducing tumor growth and increasing survival in the Kras-driven PDAC, both in immunocompetent and immunodeficient mice. Also, our data suggest that T cell-dependent immune responses are not required for the protumor effects of CD11b + Gr1 + cells, which is consistent with a recent study that showed T cell-mediated antitumor responses are not required for PDAC pathogenesis, both in mouse models and in patients (47) . Further studies are required to address these differences.
Finally, PDAC remains one of the most lethal malignancies with an average 5-y survival rate of less than 5% (48); therefore, new therapeutic strategies are urgently needed. The majority of patients diagnosed with PDAC have acquired KRAS mutations and enhanced activation of RAF/MAPK pathway, which result in enhanced cell proliferation, survival, and metastasis of the tumors (20) . Our findings point to strategies for biomarker detection and combination therapies. 
Experimental Procedures
